|
TGDS expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 4.94059999578411E-08 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
3.09730000003228E-06 |
| Normal-vs-Stage2 |
8.50549999986683E-07 |
| Normal-vs-Stage3 |
8.19069999602462E-08 |
| Normal-vs-Stage4 |
2.02889999999512E-05 |
| Stage1-vs-Stage2 |
6.186200E-02 |
| Stage1-vs-Stage3 |
9.196400E-02 |
| Stage1-vs-Stage4 |
6.295400E-01 |
| Stage2-vs-Stage3 |
5.568000E-01 |
| Stage2-vs-Stage4 |
1.968970E-01 |
| Stage3-vs-Stage4 |
3.846200E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
1.28479999972342E-08 |
| Normal-vs-AfricanAmerican |
1.552140E-02 |
| Normal-vs-Asian |
3.223700E-03 |
| Caucasian-vs-AfricanAmerican |
2.298000E-01 |
| Caucasian-vs-Asian |
1.610020E-01 |
| AfricanAmerican-vs-Asian |
9.134200E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
1.35030000514291E-08 |
| Normal-vs-Female |
5.90660000021614E-07 |
| Male-vs-Female |
1.887220E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
5.65710000000053E-05 |
| Normal-vs-Age(41-60Yrs) |
8.19890000003376E-07 |
| Normal-vs-Age(61-80Yrs) |
1.00039999617607E-08 |
| Normal-vs-Age(81-100Yrs) |
3.156700E-03 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
3.140800E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
1.286180E-02 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
2.811400E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
9.081500E-02 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
4.455600E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
8.923200E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
4.166200E-01 |
| Classical-VS-Follicular |
3.130000E-02 |
| Classical-VS-Other |
8.303200E-01 |
| Classical-VS-Normal |
2.16050000001466E-06 |
| Tall-VS-Follicular |
4.332000E-01 |
| Tall-VS-Other |
8.424600E-01 |
| Tall-VS-Normal |
1.821010E-04 |
| Follicular-VS-Other |
6.152000E-01 |
| Follicular-VS-Normal |
7.0427999998568E-07 |
| Other-VS-Normal |
5.929500E-02 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
9.61889999873122E-08 |
| Normal-vs-N1 |
3.33980000000178E-06 |
| N0-vs-N1 |
8.162400E-01 |
|
|
